OREANDA-NEWS. December 18, 2013. Having investigated a case against TEVA PHARMACEUTICAL INDUSTRIES LIMITED, the Federal Antimonopoly Service (FAS Russia) found that the international pharmaceutical company violated Clause 5 Part 1 Article 10 of the Law “On Protection of Competition” by economically and technologically unreasonable refusal to conclude a contract with “MFPDK “BIOTEK” CJSC for supplying “Copaxone-Teva”.

FAS issued a determination to TEVA PHARMACEUTICAL INDUSTRIES LIMITED.

Reference:

On 29th October 2013, FAS initiated No. 1-10-279/00-18-13 case against “TEVA PHARMACEUTICAL INDUSTRIES LIMITED” for violating Clause 5 Part 1 Article 10 of the Law “On Protection of Competition” for failure to execute a determination within the designated period.

“Copaxone-Teva” is used to treat multiple sclerosis (a disease classified by law under the category of rare diseases) and does not have any analogues.